Abstract
The gold standard of cytogenetic analysis in myelodysplastic syndromes (MDS) is conventional chromosome banding (CCB) analysis of bone marrow (BM) metaphases. Most aberrations can also be detected by fluorescence-in situ-hybridization (FISH). For this prospective multicenter German diagnostic study (www.clinicaltrials.gov: #NCT01355913) 360 patients, as yet, were followed up to 3 years by sequential FISH analyses of immunomagnetically enriched CD34+ peripheral blood (PB) cells using comprehensive FISH probe panels, resulting in a total number of 19,516 FISH analyses. We demonstrate that CD34+ PB FISH correlates significantly with CCB analysis and represents a feasible method for a reliable non-invasive cytogenetic monitoring from PB.
Copyright © 2013 Elsevier Ltd. All rights reserved.
Publication types
-
Clinical Trial
-
Multicenter Study
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Aged
-
Aged, 80 and over
-
Antigens, CD34 / blood
-
Antigens, CD34 / metabolism*
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Azacitidine / administration & dosage
-
Azacitidine / therapeutic use
-
Chromosome Aberrations / drug effects
-
Chromosome Banding / methods*
-
Female
-
Follow-Up Studies
-
Germany
-
Humans
-
In Situ Hybridization, Fluorescence / methods*
-
Lenalidomide
-
Male
-
Middle Aged
-
Myelodysplastic Syndromes / blood
-
Myelodysplastic Syndromes / drug therapy
-
Myelodysplastic Syndromes / genetics*
-
Prospective Studies
-
Thalidomide / administration & dosage
-
Thalidomide / analogs & derivatives
-
Thalidomide / therapeutic use
-
Time Factors
-
Treatment Outcome
Substances
-
Antigens, CD34
-
Thalidomide
-
Lenalidomide
-
Azacitidine
Associated data
-
ClinicalTrials.gov/NCT01355913